Home › Calculator › MYGN Dividend Calculator 2026
MYGN Dividend DRIP Calculator 2026
62.70% YieldHealthcareMyriad Genetics, Inc. · NASDAQ
Price: $3.19 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When MYGN pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your MYGN snowball 📈
$10,000 in MYGN → $597.1K in 10 years · $5,125.14/month
About Myriad Genetics, Inc. (MYGN) — Dividend Analysis 2026
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Compare MYGN with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full MYGN DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open MYGN position with:
🌍 MYGN Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold MYGN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 62.70% | 59.90% | $6,270 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 53.30% | 50.50% | $5,330 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 50.16% | 47.36% | $5,016 / yr |
| 🇬🇧 UK ISA | 0% | 62.70% | 59.90% | $6,270 / yr |
| 🇬🇧 UK Taxable | 8.75% | 57.21% | 54.41% | $5,721 / yr |
| 🇨🇦 TFSA | 0% | 62.70% | 59.90% | $6,270 / yr |
| 🇨🇦 CA Taxable | 25% | 47.03% | 44.23% | $4,703 / yr |
| 🇦🇺 Super (pension) | 15% | 53.30% | 50.50% | $5,330 / yr |
| 🇦🇺 AU Taxable | 30% | 43.89% | 41.09% | $4,389 / yr |
| 🇩🇪 DE Taxable | 26.375% | 46.16% | 43.36% | $4,616 / yr |
| 🇫🇷 FR Taxable | 30% | 43.89% | 41.09% | $4,389 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 MYGN Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 MYGN Dividend Payment Schedule
MYGN pays quarterly — 4 times per year. Next ex-div: TBD.
📊 MYGN vs Healthcare Benchmarks
How MYGN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MYGN sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ MYGN Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| F-InKind | 2026-09-03 | 4,398 | $3.23 | $14.2K | ||
| F-InKind | 2026-08-16 | 8,761 | $3.03 | $26.5K | ||
| A-Award | 2026-06-11 | 3,542 | $3.94 | $13.9K | ||
| A-Award | 2026-06-11 | 5,000 | $3.94 | $19.7K | ||
| Sale | 2026-06-08 | 15,000 | $4.46 | $66.8K | ||
| A-Award | 2026-06-04 | 59,701 | — | — | ||
| A-Award | 2026-06-04 | 59,701 | — | — | ||
| A-Award | 2026-06-04 | 59,701 | — | — | ||
| A-Award | 2026-06-04 | 59,701 | — | — | ||
| A-Award | 2026-06-04 | 59,701 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where MYGN earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MYGN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Myriad Genetics, Inc. (MYGN) is currently trading at $3.19, 91% below its 52-week high. The current dividend yield is 62.70% based on an annual payout of $2.00 per share.
MYGN (Myriad Genetics, Inc.) — 62.70% Dividend Yield Analysis
Myriad Genetics, Inc. (MYGN) is a healthcare stock currently trading at $3.19 with a dividend yield of 62.70%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (62.70%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.